19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Tyrosinemia type 1 is a hereditary disorder with liver, kidney and nervous system involvement. Neurological crises can occur in tyrosinemic patients without treatment or when treatment stops. Here we report three children that developed diaphragmatic paralysis after discontinuation of nitisinone. In patients with tyrosinemia type 1, combined treatment with nitisinone and a low-tyrosine diet have prevented neurological crises. The purpose of this article was to express the importance of taking nitisinone (NTBC) for tyrosinemia diseases and risks of inadvertent discontinuation.

          Materials & Methods

          We describe three children referred to emergency department of Nemazee Hospital, Shiraz, Iran in December 2015 with tyrosinemia type 1 who stopped NTBC treatment, presenting with respiratory. Clinical findings, laboratory results, and imaging study were assessed in three patients on admission and after starting nitisinone.

          Results

          All patients developed diaphragmatic paralysis and respiratory distress after interruption of nitisinone treatment . Two of the patients were improved after starting nitisinone. One patient expired due to respiratory failure. Full recovery occurred about 2 months after starting nitisinone.

          Conclusion

          Discontinuation of nitisinone can induce diaphragmatic paralysis and respiratory failure. Therefore, we should advise patients to use NTBC for the long term and not interrupt it.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.

          Hereditary tyrosinaemia type 1 is a rare inherited metabolic condition, which leads to a fatal multisystemic disease in childhood. Since 1992, nitisinone - a compound developed from work on triketone herbicides - has become an effective pharmacological treatment by inhibiting the enzyme 4-hydroxyphenylpyruvate dioxygenase. This review examines recent pharmacological and clinical literature on nitisinone, and assesses its impact as a pharmacological treatment for hereditary tyrosinaemia type 1. English language literature from MedLine and EmBase for nitisinone was searched from 1990 to 2008 for all papers relevant to the use of nitisinone in hereditary tyrosinaemia type 1. Nitisinone can prevent the development of liver disease and significantly reduce the risk of developing hepatocellular carcinoma; however, vigorous surveillance for the development of HCC needs to be continued lifelong.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The role of nitisinone in tyrosine pathway disorders.

            Nitisinone 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione (NTBC), an effective herbicide, is the licensed treatment for the human condition, hereditary tyrosinaemia type 1 (HT-1). Its mode of action interrupts tyrosine metabolism through inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD). Nitisinone is a remarkable safe drug to use with few side effects reported. Therefore, we propose that it should be investigated as a potential treatment for other disorders of tyrosine metabolism. These include alkaptonuria (AKU), a rare disease resulting is severe, early-onset osteoarthritis. We present a case study from the disease, and attempts to use the drug both off-label and in clinical research through the DevelopAKUre consortium.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.

              Neurological crises do not occur in patients with tyrosinaemia type I treated with NTBC. We report an 8 month-old boy with severe neurological crisis after interruption of NTBC treatment including progressive ascending polyneuropathy and diaphragmatic paralysis, arterial hypertension, respiratory distress requiring mechanical ventilation who later also developed impaired liver function and tubulopathy. After re-introduction of NTBC the patient slowly regained normal neurological functions and recovered completely.
                Bookmark

                Author and article information

                Journal
                Iran J Child Neurol
                Iran J Child Neurol
                IJCN
                Iranian Journal of Child Neurology
                Shahid Beheshti University of Medical Sciences (Tehran, Iran )
                1735-4668
                2008-0700
                Autumn 2017
                : 11
                : 4
                : 66-70
                Affiliations
                [1 ]Department of Pediatrics Gastroenterology and Hepatology, Shiraz University of Medical Sciences, Shiraz, Iran.
                [2 ]Department. of Pediatrics Hematology and Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
                [3 ]Department. of Pediatrics Intensive Care Units, Shiraz University of Medical Sciences, Shiraz, Iran.
                [4 ]Department. of Pediatrics Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
                Author notes
                Corresponding Author: Shakibazad N. MD ,Department of Pediatrics Hematology and Oncology, Shiraz University of Medical Sciences, Shiraz, Iran. Email: nshakibazad@gmail.com
                Article
                ijcn-11-066
                5703631
                29201126
                729934dd-7588-48a8-8570-80c65ca614f0

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License, ( http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 18 January 2016
                : 15 October 2016
                : 4 February 2017
                Categories
                Case Report

                tyrosinemia type 1,diaphragmatic paralysis,nitisinone,neurological crises,respiratory failure

                Comments

                Comment on this article